Glucarpidase should soon be approved throughout Europe to treat methotrexate toxicity. The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently recommended the ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2008 ASCO Annual Meeting. This abstract does not include a full text component.
A major new study has found a method to identify people who may experience blood, kidney, or liver related side effects from methotrexate, the most commonly used immune-suppressing medicine with 1.3 ...
Methotrexate is a cornerstone in oncology and immunosuppression, but its propensity to disrupt spermatogenesis, deplete antioxidants and trigger apoptosis within the testicular microenvironment ...
An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study by investigators ...
An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study by investigators ...
Please provide your email address to receive an email when new articles are posted on . Patients who received glucarpidase for acute kidney injury from methotrexate treatment had improved kidney ...
High-dose methotrexate (HD-MTX) remains a cornerstone of treatment for a range of paediatric malignancies, notably acute lymphoblastic leukaemia and osteosarcoma. Administered intravenously at doses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results